IPO News and Updates


MidCon Midstream LP, an MLP carved out of SandRidge Energy to own saltwater gathering and disposal assets in the Mid-Continent region, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The Oklahoma City, OK-based company, which was formed in 2014, plans to list on the NYSE but has not selected a ticker. BofA Merrill Lynch and Barclays are the joint bookrunners on the deal. No pricing terms were disclosed, and no income statement was provided....more

Keywords: MCON.RC, SD


Coherus BioSciences, which is developing a biosimilar version of Amgen's Enbrel treatment for inflammatory diseases, announced terms for its IPO on Friday. The Redwood City, CA-based company plans to raise $85 million by offering 6.3 million shares at a price range of $12 to $15. At the midpoint of the proposed range, it would command a fully diluted market value of $508 million. Business Enbrel is a self-injected prescription treatment marketed by Amgen (AMGN) that can be used to treat five inflammatory diseases, including rheumatoid arthritis, plaque psoriasis, psoriatic ...more

Keywords: CHRS, AMGN, Biotech


Electronic Cigarettes International Group, which markets a portfolio of acquired electronic cigarette brands, postponed its uplisting to the NASDAQ on Friday. The Nunica, MI-based company planned to raise $150 million by offering 33.3 million shares (15% insider) at a price of $4.50. The company currently trades on the OTC Bulletin Board under the symbol ECIG ($4.27 per share; $350 million market cap). The company was founded in 2010 and booked $17 million in sales for the 12 months ended June 30, 2014. It had planned to list on the NASDAQ under the symbol [ECIG]. Wells Fargo ...more

Keywords: ECIG, LO, blu


CB Pharma Acquisition, a biotech-focused blank check company backed by Coronado Biosciences, announced terms for its IPO on Thursday. The Burlington, MA-based company plans to raise $40 million by offering 4.0 million units for $10 each. At that price, CB Pharma Acquisition would command a market value of about $52 million. The company is led by Lindsay Rosenwald, the CEO of Coronado Biosciences. Coronado trades on the NASDAQ under the symbol CNDO, and has a market cap of about $81 million. Formed in 2014, CB Pharma Acquisition plans to list on the NASDAQ under the ...more

Keywords: CNLMU

Archived News Headlines
Performance Disclosure: Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than the original cost. Investors should consider the investment objectives, risks, charges and expenses carefully before investing.

As stated in the Prospectus, the total annual operating expenses for the Fund was 3.48%. The Adviser has contractually agreed to keep net expenses from exceeding 2.50% of the Fund’s average daily net assets for at least a year from the date of the Prospectus and for an indefinite period thereafter subject to annual re-approval of the agreement by the Board of Trustees. An investor cannot invest directly in an index. Index returns do not represent Fund returns. The Index does not charge management fees or brokerage expenses, nor does the Index lend securities, and no revenues from securities lending were added to the performance shown.

Definitions: Net Asset Value (NAV) of the fund is calculated by dividing the total value of all the securities in its portfolio, less any liabilities, by the number of fund shares outstanding. Market Price is current value at which an asset or service can be bought or sold. Premium/Discount is provided to show the comparison of the daily net asset value (NAV) and the midpoint of the closing bid/ask for each of the funds. The Renaissance IPO Index® (IPOUSA) is a stock market index based upon a portfolio of U.S.-listed newly public companies that includes securities prior to their inclusion in core U.S. equity portfolios. The Renaissance International IPO Index® (IPOXUS) is a stock market index based upon a portfolio of newly public companies listed on non-U.S. exchanges. The S&P 500® Index (SPX) is a stock market index based on the market capitalizations of 500 large companies whose common stock is publicly traded on the NYSE.

Risk Disclosure: Investments in the Renaissance IPO ETF, symbol "IPO", the Renaissance International IPO ETF, symbol "IPOS" (the “ETFs”), and the Global IPO Fund, symbol "IPOSX" (the “Mutual Fund”) are subject to investment risk, including possible loss of the principal amounts invested. The ETFs and the Mutual Fund (the “Funds”) invest in companies that have recently completed initial public offerings. These stocks are unseasoned equities lacking trading history, a track record of reporting to investors and widely available research coverage which many result in extreme price volatility. Due to a greater number of IPOs in certain segments, the Funds may also be subject to information technology and financial sector risk, small and mid-capitalization company risk, and, for the Renaissance International IPO ETF, emerging markets risk. The Funds may hold securities in the form of Depository Receipts, REITs, and Partnership Units which have greater risks than common shares. The strategies have high portfolio turnover and securities lending risks. The returns of the ETFs may not match the return of the respective indices. The ETFs are classified as non-diversified investment companies subject to concentration risk.

Prospectus: Investors should consider the investment objectives, risks, charges and expenses carefully before investing. For a prospectus and/or summary prospectus with this and other information, please visit www.renaissancecapital.com. Read the prospectus carefully before investing. Renaissance Capital Investments, Inc., distributor for the Mutual Fund. Foreside Fund Services, LLC, distributor for the ETFs, 1-866-486-6645.
Attribution Policy: The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: IPO ETF manager Renaissance Capital.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO), the Renaissance International IPO ETF (symbol: IPOS), or the Global IPO Fund (symbol: IPOSX), may have investments in securities of companies mentioned.